156407-78-2

Usage

Uses

Used in Pharmaceutical Industry:
(R)-tert-butoxycarbonylamino-[4-methoxy-phenyl]-acetic acid is used as a building block for the development of new pharmaceuticals. The presence of the Boc protecting group allows for controlled synthesis, preventing unwanted reactions during the drug development process. The amino and phenyl groups contribute to the compound's biological activity, making it a valuable component in the creation of bioactive molecules.
Used in Peptide Synthesis:
In the field of peptide synthesis, (R)-tert-butoxycarbonylamino-[4-methoxy-phenyl]-acetic acid serves as a crucial building block. (R)-tert-butoxycarbonylamino-[4-methoxy-phenyl]-acetic acid's structure facilitates the formation of peptide bonds, which are essential for the development of various peptide-based drugs and therapeutic agents.
Overall, (R)-tert-butoxycarbonylamino-[4-methoxy-phenyl]-acetic acid is a versatile and valuable chemical compound with applications in the pharmaceutical and biotechnology industries, particularly in the development of new drugs and therapeutic agents. Its unique structural features and potential for biological activity make it an essential component in the synthesis of various bioactive molecules.

Upstream product

• 143323-49-3 (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27460-85-1 N-(tert-butoxycarbonyl)-D-(4-hydroxyphenyl)glycine 
• 22818-40-2 D-4-hydroxyphenylglycine 
• 193073-85-7 methyl (R)-2-((tert-butoxycarbonyl)amino)-2-(4-methoxyphenyl)acetate 
• 37763-23-8 D-2-p-hydroxyphenylglycine methyl ester 

Downstream Products

• 250249-06-0 2-[2-tert-butoxycarbonylamino-2-(4-methoxy-phenyl)-acetylamino]-3-(tert-butyl-dimethyl-silanyloxy)-3-(4-hydroxy-phenyl)-propionic acid ethyl ester 
• 467427-43-6 3-[4-benzyloxy-2-(tert-butyl-dimethyl-silanyloxy)-3-chloro-phenyl]-2-[2-tert-butoxycarbonylamino-2-(4-methoxy-phenyl)-acetylamino]-3-hydroxy-propionic acid ethyl ester 
• 467427-46-9 (2S,3R)-2-[(R)-2-Amino-2-(4-methoxy-phenyl)-acetylamino]-3-[2-(tert-butyl-dimethyl-silanyloxy)-3-chloro-4-hydroxy-phenyl]-3-triisopropylsilanyloxy-propionic acid ethyl ester 
• 467427-45-8 2-[2-tert-butoxycarbonylamino-2-(4-methoxy-phenyl)-acetylamino]-3-[2-(tert-butyl-dimethyl-silanyloxy)-3-chloro-4-hydroxy-phenyl]-3-triisopropylsilanyloxy-propionic acid ethyl ester 
• 467427-44-7 3-[4-benzyloxy-2-(tert-butyl-dimethyl-silanyloxy)-3-chloro-phenyl]-2-[2-tert-butoxycarbonylamino-2-(4-methoxy-phenyl)-acetylamino]-3-triisopropylsilanyloxy-propionic acid ethyl ester 
• 467427-37-8 2-[2-{2-tert-butoxycarbonylamino-2-[3,5-dibromo-4-(pyrrolidin-1-ylazo)-phenyl]-acetylamino}-2-(4-methoxy-phenyl)-acetylamino]-3-[2-(tert-butyl-dimethyl-silanyloxy)-3-chloro-4-hydroxy-phenyl]-3-triisopropylsilanyloxy-propionic acid ethyl ester 
• 250249-08-2 (2S,3R)-2-[(R)-2-Amino-2-(4-methoxy-phenyl)-acetylamino]-3-(tert-butyl-dimethyl-silanyloxy)-3-(3-chloro-4-hydroxy-phenyl)-propionic acid ethyl ester 
• 250249-07-1 2-[2-tert-butoxycarbonylamino-2-(4-methoxy-phenyl)-acetylamino]-3-(tert-butyl-dimethyl-silanyloxy)-3-(3-chloro-4-hydroxy-phenyl)-propionic acid ethyl ester 
• 250249-09-3 (2S,3R)-2-[(R)-2-{(R)-2-tert-Butoxycarbonylamino-2-[3,5-dibromo-4-(pyrrolidin-1-ylazo)-phenyl]-acetylamino}-2-(4-methoxy-phenyl)-acetylamino]-3-(tert-butyl-dimethyl-silanyloxy)-3-(3-chloro-4-hydroxy-phenyl)-propionic acid ethyl ester 
• 947181-58-0 [[(1S,2S)-1-(4-bromo-phenylcarbamoyl)-2-phenyl-propylcarbamoyl]-((R)-4-methoxy-phenyl)-methyl]-carbamic acid tert-butyl ester 
• 876754-83-5 [(R)-[(1S,2S)-1-(4-acetyl-thiazol-2-ylcarbamoyl)-2-phenyl-propylcarbamoyl]-(4-methoxy-phenyl)-methyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

PENICILLIN-BINDING PROTEIN INHIBITORS

Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

SUBSTITUTED HYDANTOINS

This invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are described in this application. These compounds inhibit the enzymes MEK 1 and MEK2, protein kinases that are components o

Growth hormone secretagogues

What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1to C6alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.

Total synthesis of vancomycin - Part 2: Retrosynthetic analysis, synthesis of amino acid building blocks and strategy evaluations

Retrosynthetic analysis of vancomycin (1) defined vancomycin's aglycon (2) and protected triazene 3 (Figure 1) as advanced intermediates for an eventual total synthesis. Sequential assembly of 3 as shown in Figure 2 (strategy I) and Figure 3 (strategy II) led to amino acid building blocks 8-10 and 12-15, respectively, representing vancomycin's amino acids AA-1 to AA-7. These amino acid fragments were constructed by stereoselective routes and the two synthetic strategies were tested for feasibility. Strategy I, postulating construction of the vancomycin main framework in the order of D-O-E→D-O-E/C-O-D→D-O-E/C-O-D/A-B, suffered from serious epimerization problems at the AA-4 stereocenter; while strategy II, involving the sequence C-O-D→C-O-D/AB→C-O-D/AB/D-O-E proved viable. These findings set the stage for the final drive towards vancomycin's aglycon (2) and vancomycin (1).

P-Hydroxymethylphenylacetamidocephalosporins

7-(p-Hydroxymethylphenylglycylamido)cephalosporins are prepared by acylating a 7-aminocephalosporin compound. The products have antibacterial activity.